Free Trial
→ This Bitcoin bull run is different… (From Brownstone Research) (Ad) Buy LENZ Stock  Free LENZ Stock Alerts

LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics logo
$30.03 +1.07 (+3.69%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$30.03 0.00 (0.00%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for LENZ Therapeutics

Annual Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -68 -71 -101 -70 -50
Consolidated Net Income / (Loss)		 -68 -71 -101 -70 -50
Net Income / (Loss) Continuing Operations		 -68 -71 -101 -70 -50
Total Pre-Tax Income 		-68 -71 -101 -70 -50
Total Operating Income		 -14 -60 -106 -72 -59
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 60 106 72 59
Selling, General & Admin Expense		 4.38 23 33 13 29
Research & Development Expense		 9.12 38 73 60 30
Total Other Income / (Expense), net		 -55 -10 4.59 2.28 8.84
Interest & Investment Income		 - - - 2.19 8.55
Other Income / (Expense), net		 -55 -10 4.59 0.09 0.29
Income Tax Expense		 - - - -0.18 0.00
Basic Earnings per Share		 ($29.93) ($2.45) ($1.84) ($35.71) ($2.34)
Weighted Average Basic Shares Outstanding		 2.28M 28.92M 54.87M 1.96M 21.28M
Diluted Earnings per Share		 ($29.93) ($2.45) ($1.84) ($35.71) ($2.34)
Weighted Average Diluted Shares Outstanding		 2.28M 28.92M 54.87M 1.96M 21.28M
Weighted Average Basic & Diluted Shares Outstanding		 2.28M 28.92M 58.16M 58.24M 27.54M

Quarterly Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15
Consolidated Net Income / (Loss)		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15
Net Income / (Loss) Continuing Operations		 -25 -24 -13 -15 -19 -24 -17 -10 -10 -13 -15
Total Pre-Tax Income 		-25 -24 -13 -15 -19 -24 -17 -10 -10 -13 -15
Total Operating Income		 -26 -27 -13 -15 -20 -25 -16 -14 -13 -15 -17
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 26 27 13 15 20 25 16 14 13 15 17
Selling, General & Admin Expense		 7.85 8.29 2.29 2.32 2.86 5.45 5.55 7.41 6.49 9.36 11
Research & Development Expense		 18 18 10 13 17 20 11 6.95 6.45 5.87 5.82
Total Other Income / (Expense), net		 1.47 2.28 -0.05 0.23 0.99 1.12 -0.56 4.10 2.73 2.57 2.31
Interest & Investment Income		 - - 0.00 0.25 1.09 0.85 0.79 2.46 2.74 2.57 2.32
Other Income / (Expense), net		 1.47 2.28 -0.05 -0.02 -0.10 0.27 -1.35 1.64 -0.01 0.01 -0.01
Basic Earnings per Share		 ($0.45) ($0.43) ($6.50) ($7.53) ($9.62) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53)
Weighted Average Basic Shares Outstanding		 55.21M 54.87M 1.95M 1.96M 1.96M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M
Diluted Earnings per Share		 ($0.45) ($0.43) ($6.50) ($7.53) ($9.62) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53)
Weighted Average Diluted Shares Outstanding		 55.21M 54.87M 1.95M 1.96M 1.96M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M
Weighted Average Basic & Diluted Shares Outstanding		 58.15M 58.16M 58.10M 57.98M 58.00M 58.24M 25.53M 27.50M 27.50M 27.54M 28.15M

Annual Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 20 359 -329 -9.30 -15
Net Cash From Operating Activities		 -8.72 -53 -88 -60 -59
Net Cash From Continuing Operating Activities		 -8.72 -53 -88 -60 -59
Net Income / (Loss) Continuing Operations		 -68 -71 -101 -70 -50
Consolidated Net Income / (Loss)		 -68 -71 -101 -70 -50
Depreciation Expense		 0.12 0.73 2.35 0.02 0.06
Amortization Expense		 - 0.00 -1.60 -1.06 -4.02
Non-Cash Adjustments To Reconcile Net Income		 60 19 20 1.41 7.43
Changes in Operating Assets and Liabilities, net		 -0.06 -1.37 -7.30 9.41 -13
Net Cash From Investing Activities		 -1.55 -5.74 -242 -30 -154
Net Cash From Continuing Investing Activities		 -1.55 -5.74 -242 -30 -154
Purchase of Property, Plant & Equipment		 -1.55 -5.74 -6.59 -0.03 -0.47
Purchase of Investments		 - 0.00 -406 -52 -242
Sale and/or Maturity of Investments		 - 0.00 170 23 88
Net Cash From Financing Activities		 30 417 0.60 81 199
Net Cash From Continuing Financing Activities		 30 417 0.60 81 199
Repurchase of Common Equity		 - - -0.08 -2.48 0.00
Issuance of Preferred Equity		 25 166 - 83 0.00
Issuance of Common Equity		 0.26 252 0.66 0.00 80
Other Financing Activities, net		 0.00 0.03 0.02 0.20 119

Quarterly Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -19 -8.66 70 -40 -32 -7.71 165 -116 -43 -21 2.88
Net Cash From Operating Activities		 -22 -22 -13 -14 -13 -21 -24 -16 -11 -9.08 -16
Net Cash From Continuing Operating Activities		 -22 -22 -13 -14 -13 -21 -24 -16 -11 -9.08 -16
Net Income / (Loss) Continuing Operations		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15
Consolidated Net Income / (Loss)		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13 -15
Depreciation Expense		 0.65 0.68 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.03 0.04
Amortization Expense		 -0.56 -1.12 0.00 -0.02 -0.53 -0.51 -0.28 -0.96 -1.36 -1.42 -1.13
Non-Cash Adjustments To Reconcile Net Income		 4.62 5.53 0.16 0.21 0.60 0.44 1.99 1.60 2.19 1.65 2.56
Changes in Operating Assets and Liabilities, net		 -2.24 -2.92 -0.29 1.00 5.72 2.98 -9.01 -6.20 -1.21 3.33 -2.97
Net Cash From Investing Activities		 3.50 14 -0.01 -27 -18 15 18 -98 -62 -12 19
Net Cash From Continuing Investing Activities		 3.50 14 -0.01 -27 -18 15 18 -98 -62 -12 19
Purchase of Property, Plant & Equipment		 -0.92 -1.02 -0.01 -0.02 - - 0.00 -0.13 -0.19 -0.15 -0.11
Purchase of Investments		 -86 -66 - - -19 -5.83 0.00 - -84 -47 -33
Sale and/or Maturity of Investments		 90 80 0.00 - 1.50 21 18 13 22 35 52
Net Cash From Financing Activities		 -0.06 0.24 83 - -0.57 -1.91 171 -2.14 30 0.05 0.04
Net Cash From Continuing Financing Activities		 -0.06 0.24 83 - -0.57 -1.91 171 -2.14 30 0.05 0.04
Issuance of Common Equity		 - 0.24 0.00 - - - 53 -3.56 30 -0.09 0.00
Other Financing Activities, net		 0.01 0.00 0.20 - - - 118 1.43 0.04 0.14 0.04

Annual Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 23 402 322 70 215
Total Current Assets		 21 382 275 67 212
Cash & Equivalents		 20 377 48 35 20
Restricted Cash		 0.04 - 0.00 0.00 0.11
Short-Term Investments		 - 0.00 220 31 189
Prepaid Expenses		 1.29 4.76 7.14 1.45 2.77
Plant, Property, & Equipment, net		 1.46 6.51 23 0.05 0.65
Total Noncurrent Assets		 0.00 14 24 3.08 2.74
Other Noncurrent Operating Assets		 0.00 14 8.59 3.08 2.74
Total Liabilities & Shareholders' Equity		 23 402 322 70 215
Total Liabilities		 32 18 26 20 11
Total Current Liabilities		 32 12 13 19 10
Accounts Payable		 0.63 2.45 2.61 5.71 4.26
Accrued Expenses		 1.89 1.52 2.59 13 6.15
Total Noncurrent Liabilities		 0.32 5.79 13 1.18 0.81
Other Noncurrent Operating Liabilities		 0.32 5.79 13 1.18 0.81
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -65 384 296 -93 204
Total Preferred & Common Equity		 -65 384 296 -93 204
Total Common Equity		 -65 384 296 -93 204
Common Stock		 5.18 525 540 2.53 349
Retained Earnings		 -71 -141 -242 -95 -145
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -1.05 0.01 0.20

Quarterly Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 354 335 310 287 266 217 203 224 201
Total Current Assets		 327 298 270 251 239 217 199 221 198
Cash & Equivalents		 75 56 70 129 183 200 84 41 23
Restricted Cash		 - - - - - 0.11 0.11 0.11 0.11
Short-Term Investments		 247 235 194 118 51 13 112 176 171
Prepaid Expenses		 4.35 6.81 6.21 2.88 4.78 3.28 3.12 3.48 3.77
Plant, Property, & Equipment, net		 10 13 33 18 13 0.05 0.16 0.37 0.93
Total Noncurrent Assets		 17 23 6.62 18 15 0.60 3.13 2.93 2.47
Other Noncurrent Operating Assets		 11 9.68 6.62 18 15 0.60 3.13 2.93 2.47
Total Liabilities & Shareholders' Equity		 354 335 310 287 266 217 203 224 201
Total Liabilities		 15 18 34 63 62 19 9.72 8.73 9.24
Total Current Liabilities		 12 14 14 12 13 19 8.58 7.71 8.57
Accounts Payable		 3.62 3.97 1.99 2.72 3.75 7.13 4.41 2.76 3.66
Accrued Expenses		 1.34 1.65 7.91 4.37 3.45 12 4.18 4.95 4.91
Total Noncurrent Liabilities		 3.26 4.87 19 51 50 0.27 1.14 1.02 0.67
Other Noncurrent Operating Liabilities		 3.26 4.87 19 51 50 0.27 1.14 1.02 0.67
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 338 316 276 224 204 198 193 215 192
Total Preferred & Common Equity		 338 316 276 224 204 198 193 215 192
Total Common Equity		 338 316 276 224 204 198 193 215 192
Common Stock		 533 536 543 546 548 310 315 347 352
Retained Earnings		 -193 -218 -266 -322 -344 -112 -122 -132 -160
Accumulated Other Comprehensive Income / (Loss)		 -1.03 -1.60 -0.47 -0.27 -0.10 -0.00 -0.06 0.52 0.12

Annual Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -2.66% -43.23% 26.84% 15.12%
EBIT Growth		 0.00% -3.55% -42.81% 28.42% 19.37%
NOPAT Growth		 0.00% -347.73% -74.77% 31.44% 19.08%
Net Income Growth		 0.00% -3.49% -42.81% 30.76% 28.87%
EPS Growth		 0.00% 91.81% 24.90% -1,840.76% 93.45%
Operating Cash Flow Growth		 0.00% -506.03% -66.46% 31.37% 1.64%
Free Cash Flow Firm Growth		 0.00% 0.00% -0.77% 71.31% -123.61%
Invested Capital Growth		 0.00% 123.88% 80.10% -218.65% 66.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -6.72% -0.43% 47.32%
EBIT Q/Q Growth		 0.00% 0.00% -5.81% -0.34% 51.46%
NOPAT Q/Q Growth		 0.00% 0.00% -7.98% 2.38% 55.31%
Net Income Q/Q Growth		 0.00% 0.00% -33.54% 1.28% 56.51%
EPS Q/Q Growth		 0.00% 0.00% -132.74% -48.30% -113.64%
Operating Cash Flow Q/Q Growth		 0.00% -24.27% -8.42% 2.36% 41.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -115.89% 57.37%
Invested Capital Q/Q Growth		 0.00% 0.00% 12.10% 49.59% -160.69%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 99.74% 100.00%
Interest Burden Percent		 100.06% 100.00% 100.00% 96.97% 85.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 697.68% -37.81% -29.71% -40.33% -39.07%
Cash Return on Invested Capital (CROIC)		 0.00% -1,116.78% -803.61% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4,656.54% -32.20% -29.71% -23.66% -17.08%
Return on Equity Simple (ROE_SIMPLE)		 104.53% -18.42% -34.11% 75.47% -24.39%
Net Operating Profit after Tax (NOPAT)		 -9.45 -42 -74 -51 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -297.34% -14.34% -8.21% -11.03% -6.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 54.69% -20.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -68 -71 -101 -72 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -68 -70 -100 -73 -62
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 1.88 0.65 0.00 3.89
Price to Tangible Book Value (P/TBV)		 0.00 1.88 0.65 0.00 3.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 48.76 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 2.02 -1.06 -0.97 -1.01 -1.08
Leverage Ratio		 -2.30 1.13 1.06 1.13 1.12
Compound Leverage Factor		 -2.30 1.13 1.06 1.10 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -567.43% 0.00% 0.00% 282.94% 0.00%
Common Equity to Total Capital		 667.43% 100.00% 100.00% -182.94% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -11.32 24.18 3.41 0.17 41.74
Noncontrolling Interest Sharing Ratio		 -567.43% 14.86% 0.00% 41.33% 56.28%
Liquidity Ratios		 - - - - -
Current Ratio		 0.66 31.44 21.11 3.63 20.36
Quick Ratio		 0.62 31.04 20.57 3.55 20.09
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -79 -80 -23 -51
Operating Cash Flow to CapEx		 -564.47% -920.77% -1,334.24% -201,266.67% -12,690.38%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -218.03 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -256.65 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -30 7.07 13 -15 -5.06
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 37 5.67 -28 10
Enterprise Value (EV)		 232 345 -90 230 585
Market Capitalization		 196 722 193 152 794
Book Value per Share		 ($28.64) $6.61 $5.10 ($1.60) $7.42
Tangible Book Value per Share		 ($28.64) $6.61 $5.10 ($1.60) $7.42
Total Capital		 -9.80 384 296 51 204
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -20 -377 -284 -66 -209
Capital Expenditures (CapEx)		 1.55 5.74 6.59 0.03 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -31 -7.38 -5.91 -17 -7.63
Debt-free Net Working Capital (DFNWC)		 -11 370 262 49 202
Net Working Capital (NWC)		 -11 370 262 49 202
Net Nonoperating Expense (NNE)		 59 28 27 19 8.74
Net Nonoperating Obligations (NNO)		 -20 -377 -284 -66 -209
Total Depreciation and Amortization (D&A)		 0.12 0.73 0.75 -1.04 -3.96
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.45) ($1.84) ($2.19) ($2.34)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 58.01M 54.87M 57.02M 21.28M
Adjusted Diluted Earnings per Share		 $0.00 ($2.45) ($1.84) ($2.19) ($2.34)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 58.01M 54.87M 57.02M 21.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.45) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 28.92M 58.16M 58.24M 27.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.45 -42 -74 -51 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -1,708.33 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -236.25 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -1,746.95 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -274.88 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.08% -3.54% 0.00%

Quarterly Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -70.85% -33.95% 50.27% 40.79% 16.68% -1.26% -39.78% 8.90% 30.21% 34.14% -1.89%
EBIT Growth		 -69.15% -29.30% 51.19% 42.25% 19.11% -1.01% -37.62% 15.09% 35.13% 38.45% 2.83%
NOPAT Growth		 -79.11% -41.24% 51.40% 44.13% 24.05% 6.59% -27.52% 4.06% 34.84% 39.07% -5.24%
Net Income Growth		 -69.15% -3,257.77% 50.96% 43.22% 23.51% 3.69% -31.40% 30.37% 45.90% 46.60% 12.19%
EPS Growth		 -60.71% -106.12% -1,254.17% -1,468.75% -2,037.78% -2,704.65% 45.69% 94.69% 96.05% 116.34% 84.99%
Operating Cash Flow Growth		 -44.13% -43.84% 39.75% 38.79% 41.09% 6.51% -87.04% -16.79% 19.16% 56.71% 32.95%
Free Cash Flow Firm Growth		 -59.05% 0.00% 56.98% 174.89% 212.05% 142.49% 236.73% -229.50% -235.20% -299.87% -255.34%
Invested Capital Growth		 119.44% 80.10% 31.97% -337.29% -363.85% -218.65% -225.54% 86.31% 93.53% 66.53% 86.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 2.88% -1.31% 49.16% -18.35% -36.67% -23.14% 74.49% 22.86% -4.70% -16.20% -8.57%
EBIT Q/Q Growth		 4.84% 0.83% 48.24% -18.21% -33.31% -23.83% 76.60% 27.06% -1.84% -17.50% -11.34%
NOPAT Q/Q Growth		 2.32% -2.28% 52.84% -18.57% -32.80% -25.79% 80.52% 10.79% 9.80% -17.61% -11.21%
Net Income Q/Q Growth		 4.84% 0.34% 48.49% -16.23% -28.21% -25.49% 77.47% 38.41% 0.38% -23.86% -15.55%
EPS Q/Q Growth		 6.25% 4.44% -1,411.63% -15.85% -27.76% -25.36% -128.86% 88.67% 5.00% 618.42% -126.90%
Operating Cash Flow Q/Q Growth		 -0.56% -0.95% 42.94% -5.67% 3.22% -60.22% 47.82% 34.01% 33.01% 14.20% -76.79%
Free Cash Flow Firm Q/Q Growth		 23.09% 0.42% 51.75% 302.66% 15.07% -62.24% 153.72% -291.94% -20.13% 44.18% -20.68%
Invested Capital Q/Q Growth		 11.68% 12.10% -4.80% -299.10% -24.19% 49.59% -0.73% 78.29% 41.27% -160.69% 58.89%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.50% 100.00% 100.00% 100.00% 99.25% 100.00% 100.00% 100.00% 100.01% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 98.32% 94.56% 96.55% 95.48% 80.63% 78.87% 83.14% 86.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -21.12% -29.71% -27.57% -27.26% -27.23% -40.33% -53.79% -59.04% -54.59% -39.07% -24.47%
Cash Return on Invested Capital (CROIC)		 0.00% -803.61% -633.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -21.12% -29.71% -27.57% -27.26% -27.23% -23.66% -53.79% -59.04% -54.59% -17.08% -24.47%
Return on Equity Simple (ROE_SIMPLE)		 -23.91% 0.00% -31.82% -34.21% -34.74% 0.00% -64.38% -63.81% -53.16% 0.00% -24.86%
Net Operating Profit after Tax (NOPAT)		 -18 -19 -8.83 -10 -14 -17 -11 -10 -9.06 -11 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.82% -1.78% -1.25% -1.48% -1.85% -3.55% -2.26% -0.09% -0.51% -1.45% -1.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 18.87% - - - -5.22% -6.17%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -24 -13 -15 -20 -25 -17 -13 -13 -15 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -25 -13 -15 -20 -25 -18 -14 -14 -17 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.58 0.65 0.52 0.67 0.70 0.00 6.54 2.29 3.03 3.89 3.69
Price to Tangible Book Value (P/TBV)		 0.58 0.65 0.52 0.67 0.70 0.00 6.54 2.29 3.03 3.89 3.69
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.97 -0.97 -1.02 -1.04 -1.01 -1.01 -1.07 -1.08 -1.08 -1.04
Leverage Ratio		 1.05 1.06 1.08 1.14 1.15 1.13 1.11 1.17 1.17 1.12 1.07
Compound Leverage Factor		 1.05 1.06 1.08 1.12 1.09 1.09 1.06 0.95 0.92 0.93 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 282.94% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -182.94% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.89 4.20 2.18 0.70 0.35 2.41 40.67 27.34 45.00 42.40 45.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 41.33% 0.00% 0.00% 0.00% 56.28% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 22.07 21.11 18.85 20.47 19.05 3.63 11.47 23.23 28.63 20.36 23.09
Quick Ratio		 21.57 20.57 18.42 20.10 18.66 3.55 11.29 22.85 28.16 20.09 22.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -24 -12 24 27 10 16 -31 -37 -21 -25
Operating Cash Flow to CapEx		 -2,428.09% -2,196.77% -213,300.00% -56,350.00% 0.00% 0.00% 0.00% -11,875.94% -5,688.71% -6,092.62% -14,590.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 13 12 -24 -30 -15 -15 -3.31 -1.94 -5.06 -2.08
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 6.19 5.67 2.94 -34 -41 -28 -27 21 28 10 13
Enterprise Value (EV)		 -121 -90 -122 -96 -90 230 1,082 245 436 585 514
Market Capitalization		 185 193 143 151 144 152 1,295 441 653 794 708
Book Value per Share		 $5.44 $5.10 $4.75 $3.86 $3.52 ($1.60) $42.01 $7.56 $7.83 $7.42 $6.97
Tangible Book Value per Share		 $5.44 $5.10 $4.75 $3.86 $3.52 ($1.60) $42.01 $7.56 $7.83 $7.42 $6.97
Total Capital		 316 296 276 224 204 51 198 193 215 204 192
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -305 -284 -264 -247 -234 -66 -213 -196 -217 -209 -194
Capital Expenditures (CapEx)		 0.92 1.02 0.01 0.02 0.00 0.00 0.00 0.13 0.19 0.15 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.72 -5.91 -8.13 -7.76 -7.74 -17 -16 -5.46 -4.23 -7.63 -4.80
Debt-free Net Working Capital (DFNWC)		 285 262 256 239 226 49 198 191 213 202 189
Net Working Capital (NWC)		 285 262 256 239 226 49 198 191 213 202 189
Net Nonoperating Expense (NNE)		 6.37 5.87 3.84 4.25 4.97 6.20 5.39 0.21 1.15 1.99 2.77
Net Nonoperating Obligations (NNO)		 -305 -284 -264 -248 -234 -66 -213 -196 -217 -209 -194
Total Depreciation and Amortization (D&A)		 0.09 -0.44 0.00 -0.02 -0.52 -0.51 -0.27 -0.94 -1.35 -1.40 -1.10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.43) ($0.43) ($0.97) ($0.39) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53)
Adjusted Weighted Average Basic Shares Outstanding		 55.21M 54.87M 55.86M 56.75M 57.26M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.43) ($0.43) ($0.97) ($0.39) ($12.06) ($3.53) ($0.40) ($0.38) $1.97 ($0.53)
Adjusted Weighted Average Diluted Shares Outstanding		 55.21M 54.87M 55.86M 56.75M 57.26M 1.96M 4.72M 25.61M 27.17M 21.28M 27.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.15M 58.16M 58.10M 57.98M 58.00M 58.24M 25.53M 27.50M 27.50M 27.54M 28.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -19 -8.83 -10 -14 -17 -11 -10 -9.06 -11 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.08% 0.00% 0.00% 0.00% -3.54% 0.00% 0.00% 0.44% 0.00% 0.00%

Key Financial Trends

LENZ Therapeutics reported Q1 2025 results that continue to reflect a development-stage biotech with no product revenue but strong financial assets. The company generated no sales but incurred a $14.6 million net loss (–$0.53 EPS), slightly narrower than the prior year. Operating cash burn remains around $16 million per quarter, funded largely by short‐term investments and prior equity issuances. Balance sheet strength remains a standout feature, with cash and short‐term investments totaling $193 million and no debt.

  • Cash and short-term investments of $193 million at quarter end provide a strong liquidity cushion.
  • The company carries zero debt, resulting in a net cash position (cash > liabilities) of approximately $194 million.
  • Interest and investment income rose to $2.32 million in Q1 2025 from $0.79 million a year ago, partially offsetting operating losses.
  • Year-over-year net loss narrowed to $14.6 million (–$0.53 EPS) from $16.6 million (–$3.53 EPS) in Q1 2024, reflecting share count dilution and higher non-operating income.
  • Revenue remains at $0 for nine consecutive quarters, consistent with pre-commercial status.
  • Operating cash flow outflow of roughly $16 million per quarter underscores ongoing R&D and SG&A spending requirements.
  • R&D expense declined to $5.8 million in Q1 2025 versus $10.5 million a year ago, suggesting potential shifts in development priorities.
  • Altman Z-Score of 45.7 remains unusually high, driven by large cash balances and minimal liabilities despite no revenue.
  • SG&A expense surged to $11.1 million in Q1 2025 from $5.6 million in Q1 2024, increasing the quarterly cash burn rate.
  • Free cash flow to firm (FCFF) was –$25.0 million in Q1 2025, highlighting the magnitude of funding needed to advance pipelines.
06/20/25 12:41 AMAI Generated. May Contain Errors.

Frequently Asked Questions About LENZ Therapeutics' Financials

When does LENZ Therapeutics' financial year end?

According to the most recent income statement we have on file, LENZ Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has LENZ Therapeutics' net income changed over the last 4 years?

LENZ Therapeutics' net income appears to be on a downward trend, with a most recent value of -$49.77 million in 2024, falling from -$68.37 million in 2020. The previous period was -$69.97 million in 2023. Check out LENZ Therapeutics' forecast to explore projected trends and price targets.

What is LENZ Therapeutics' operating income?
LENZ Therapeutics' total operating income in 2024 was -$58.61 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.61 million
How has LENZ Therapeutics' revenue changed over the last 4 years?

Over the last 4 years, LENZ Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does LENZ Therapeutics have?

LENZ Therapeutics' total liabilities were at $11.22 million at the end of 2024, a 43.0% decrease from 2023, and a 65.3% decrease since 2020.

How much cash does LENZ Therapeutics have?

In the past 4 years, LENZ Therapeutics' cash and equivalents has ranged from $19.78 million in 2020 to $376.98 million in 2021, and is currently $20.16 million as of their latest financial filing in 2024.

How has LENZ Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, LENZ Therapeutics' book value per share changed from -28.64 in 2020 to 7.42 in 2024, a change of -125.9%.


Related Companies

This page (NASDAQ:LENZ) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners
379 passengers walked away from this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Why Is President Trump Fast-Tracking These Companies?
Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...
InvestorPlace | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump’s true trade war strategy
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...
Porter & Company | Sponsored
Most Bitcoin holders have no idea this exists
Here’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...
Brownstone Research | Sponsored
War-Proof Power
Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...
Stansberry Research | Sponsored
When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored